Literature DB >> 25034157

Pathogenesis and treatment of atherosclerosis in lupus.

Maureen McMahon1, Brian Skaggs2.   

Abstract

The prevalence of atherosclerosis (ATH) is higher in patients with systemic lupus erythematosus (SLE) and occurs at an earlier age. The lupus-related factors that account for this increased risk are likely numerous and related to the factors described in this article. Identifying of at-risk subjects and increasing the understanding of pathogenesis of ATH in SLE is critical for improving the quality of care and improving mortality in this vulnerable population.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Cardiovascular diseases; Cytokine; Proinflammatory lipids; Systemic lupus erythematosus

Mesh：

Substances：

Year:  2014        PMID： 25034157      PMCID： PMC6152881          DOI： 10.1016/j.rdc.2014.04.003

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN： 0889-857X            Impact factor:   2.670


  149 in total

1.  Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus.

Authors:  M B Urowitz; D Gladman; D Ibañez; S C Bae; J Sanchez-Guerrero; C Gordon; A Clarke; S Bernatsky; P R Fortin; J G Hanly; D J Wallace; D Isenberg; A Rahman; G S Alarcón; J T Merrill; E Ginzler; M Khamashta; O Nived; G Sturfelt; I N Bruce; K Steinsson; S Manzi; R Ramsey-Goldman; M A Dooley; A Zoma; K Kalunian; M Ramos; R F Van Vollenhoven; C Aranow; T Stoll; M Petri; P Maddison
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-06       Impact factor: 4.794

2.  Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies.

Authors:  E F Borba; E Bonfá
Journal:  Lupus       Date:  1997       Impact factor: 2.911

Review 3.  Secondary dyslipidemia. Inadvertent effects of drugs in clinical practice.

Authors:  Y Henkin; J A Como; A Oberman
Journal:  JAMA       Date:  1992-02-19       Impact factor: 56.272

4.  Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures.

Authors:  B J Van Lenten; S Y Hama; F C de Beer; D M Stafforini; T M McIntyre; S M Prescott; B N La Du; A M Fogelman; M Navab
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

5.  A novel anti-inflammatory role for simvastatin in inflammatory arthritis.

Authors:  Bernard P Leung; Naveed Sattar; Anne Crilly; Morag Prach; David W McCarey; Helen Payne; Rajan Madhok; Carol Campbell; J Alastair Gracie; Foo Y Liew; Iain B McInnes
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

6.  Poor outcomes after acute myocardial infarction in systemic lupus erythematosus.

Authors:  Mansi A Shah; Amber M Shah; Eswar Krishnan
Journal:  J Rheumatol       Date:  2009-01-22       Impact factor: 4.666

7.  Antibodies toward high-density lipoprotein components inhibit paraoxonase activity in patients with systemic lupus erythematosus.

Authors:  J R Batuca; P R J Ames; D A Isenberg; J Delgado Alves
Journal:  Ann N Y Acad Sci       Date:  2007-06       Impact factor: 5.691

Review 8.  Drug-induced lupus erythematosus.

Authors:  Camilla Dalle Vedove; Micol Del Giglio; Donatella Schena; Giampiero Girolomoni
Journal:  Arch Dermatol Res       Date:  2008-09-17       Impact factor: 3.017

9.  Risk factors for coronary artery disease in patients with systemic lupus erythematosus.

Authors:  M Petri; S Perez-Gutthann; D Spence; M C Hochberg
Journal:  Am J Med       Date:  1992-11       Impact factor: 4.965

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245
View more
  9 in total

Review 1.  Emerging risk biomarkers in cardiovascular diseases and disorders.

Authors:  Ravi Kant Upadhyay
Journal:  J Lipids       Date:  2015-04-08

Review 2.  Accelerated vascular disease in systemic lupus erythematosus: role of macrophage.

Authors:  Mohammed M Al Gadban; Mohamed M Alwan; Kent J Smith; Samar M Hammad
Journal:  Clin Immunol       Date:  2015-01-28       Impact factor: 3.969

3.  miR-185 silencing promotes the progression of atherosclerosis via targeting stromal interaction molecule 1.

Authors:  Ming Fang; Yanfei Li; Yingbiao Wu; Zhongping Ning; Xuejun Wang; Xinming Li
Journal:  Cell Cycle       Date:  2019-03-20       Impact factor: 4.534

4.  Three Clinical Clusters Identified through Hierarchical Cluster Analysis Using Initial Laboratory Findings in Korean Patients with Systemic Lupus Erythematosus.

Authors:  Ju-Yang Jung; Hyun-Young Lee; Eunyoung Lee; Hyoun-Ah Kim; Dukyong Yoon; Chang-Hee Suh
Journal:  J Clin Med       Date:  2022-04-25       Impact factor: 4.964

5.  Lipid profile among girls with systemic lupus erythematosus.

Authors:  Daniele Machado; Roseli O S Sarni; Thaís T O Abad; Simone G L Silva; Eugênia J B Khazaal; Sonia Hix; Milena S G Correia; Fabíola I Suano-Souza; Claudio A Len; Maria Teresa R A Terreri
Journal:  Rheumatol Int       Date:  2015-11-16       Impact factor: 2.631

Review 6.  Understanding Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Toward Better Treatment and Prevention.

Authors:  Allison B Reiss; Benna Jacob; Saba Ahmed; Steven E Carsons; Joshua DeLeon
Journal:  Inflammation       Date:  2021-04-05       Impact factor: 4.092

7.  Coronary artery disease is a significant cause of morbidity and premature death in patients with systemic lupus erythematosus.

Authors:  Anna Karpińska; Michał Ciurzyński
Journal:  Reumatologia       Date:  2015-05-18

8.  Predictors of peripheral arterial disease in SLE change with patient's age.

Authors:  Jose-Gabriel Erdozain; Irama Villar; Javier Nieto; Ioana Ruiz-Arruza; Guillermo Ruiz-Irastorza
Journal:  Lupus Sci Med       Date:  2017-01-12

9.  Type-I interferons in atherosclerosis.

Authors:  Hung-Jen Chen; Sander W Tas; Menno P J de Winther
Journal:  J Exp Med       Date:  2020-01-06       Impact factor: 14.307
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.